Table 3

Pneumococcal (Spn) carriage, 7-valent pneumococcal conjugate vaccine (7PCV) uptake, carriage of 7PCV and 23PPV types, recent antimicrobial use, and carriage of non-susceptible pneumococci in children 0 to 6 years of age, by region and year.

Region

Central Australia

Darwin Rural¥

East Arnhem

Katherine West

Year

2003

2005

2003

2005

2003

2005

2003

2005

No. communities

11

2

6

6

7

4

5

5

No. children swabbed

158

65

320

376

315

223

109

154


Percent children (95% Confidence Interval)


Spn positive

83(77–89)

86(78–95)

79(75–84)

67(62–72)*

85(81–89)

87(83–92)

82(74–89)

78(71–85)


Vaccinated (> = 1 dose)

96(93–99)

97(93–101)

88(84–91)

96(94–98)*

80(76–84)

97(95–99)*

89(83–95)

94(90–98)


Vaccinated (primary)

85(79–90)

83(74–92)

79(75–84)

87(84–90)*

71(66–76)

82(77–87)*

70(61–78)

82(76–89)


Vaccinated (primary+23v)

46(39–54)

54(41–66)

34(29–39)

65(60–69)*

30(24–34)

59(52–65)*

39(29–48)

62(54–69)*


7PCV-type positive

10(5–14)

12(4–21)

15(11–19)

9(6–12)

10(7–13)

10(6–14)

6(2–11)

3(0–5)


Serotype in 23PPV not in 7PCV

41(33–49)

40(29–52)

33(27–38)

25(21–29)

26(21–33)

23(17–28)

30(22–39)

31(23–38)


19A

14(8–19)

15(6–24)

17(12–21)

10(7–13)

8(5–11)

6(3–9)

5(1–9)

10(5–14)


6A

0.6(-1–2)

3(-1–7)

3(1–5)

2(0–3)

6(4–9)

4(2–7)

6(1–10)

1(0–3)


6C

3(0–6)

2(-2–5)

4(2–7)

3(1–5)

6(3–8)

7(3–10)

2(-1–4)

5(2–9)


16F

10(5–15)

11(3–19)

12(8–15)

12(8–15)

11(7–14)

10(6–14)

19(12–27)

6(2–9)*


Prescribed beta-lactam

28(21–35)

38(26–51)

17(13–21)

16(12–20)

7(4–9)

12(7–16)

9(4–15)

10(5–14)


Penicillin non-susceptible (MIC ≥ 0.12 μg/mL)

25(19–32)

42(29–54)

18(14–22)

9(6–12)*

14(10–18)

16(11–21)

13(6–19)

13(8–18)


Prescribed macrolide

0

2(-2–5)

3(1–5)

13(9–16)*

0

0

2(-1–4)

2(0–4)


Azithromycin resistant (MIC ≥ 2 μg/mL)

9(4–12)

22(11–32)

3(1–5)

5(3–8)

3(1–4)

3(1–5)

11(5–17)

5(1–8)


*95% confidence interval not overlapping with previous year. MIC = Minimum inhibitory concentration.

¥Note: One large community had participated in a trachoma eradication program involving mass azithromycin treatment in the weeks before our 2005 survey; carriage was 48% (22/45) in children with a record of recent treatment and 51% (36/70) in children with no record of recent treatment.

Leach et al. BMC Infectious Diseases 2009 9:121   doi:10.1186/1471-2334-9-121

Open Data